Journal article · 2025 · Open access

Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study

Claudio Costantino, Emanuele Amodio, Rosario Asciutto, Costanza Affranchi, Franco Belbruno, Nicole Bonaccorso, Sonia Cilia, Fabio Massimo Contarino, Vincenzo Di Gaetano, Francesco Di Gregorio, Angelo Foresta, Roberto Furnari and 11 more

Vaccines, 13(12), 1219 · Published 2 December 2025 · DOI 10.3390/vaccines13121219

Open PDFView at the publisherCite this paper

In brief

“Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study” is a 2025 journal article by Claudio Costantino and 22 co-authors, published in Vaccines. OpenAlex counts 11 citations as of 18 November 2026, which puts it in the top 2% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Vaccines.

Citations
11
Most cited in
2026 (11)
Field-weighted impact
5.99
References
30
Authors
23

Abstract

Objectives: The introduction of universal prophylaxis with Nirsevimab represents a major innovation in preventing respiratory syncytial virus (RSV) infections in newborns. In Sicily, Nirsevimab administration began on 1 November 2024, for all newborns under one year and at-risk infants during the 2024–2025 season. This study assessed the real-world impact of this strategy in reducing RSV-related hospitalizations. Methods: This retrospective cohort study examined newborns residing in Sicily from 2015 to May 2025, evaluating hospitalization incidence rates attributable to RSV during the first year of life. RSV hospitalizations were identified using ICD-9 codes (079.6, 466.11, 480.1) in any diagnostic position. Incidence rates in the 2024–2025 season (intervention period) were compared with preceding seasons. Results: During the study period, 4431 RSV hospitalization cases occurred (19.84 cases per 1000 person-years), peaking in 2023–2024 (53.47 cases per 1000 person-years). A statistically significant 40% reduction in RSV hospitalizations was observed during the 2024–2025 season (October–April) compared with the preceding season, with a relative reduction ranging between 33.4% and 54.8% across sensitivity models. Conclusions: These results confirm the significant impact of the universal prophylaxis program in real-world practice, consistent with other European programs. These findings support universal RSV prevention strategies and provide insights for optimizing regional and national health policies.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Costantino, C., Amodio, E., Asciutto, R., Affranchi, C., Belbruno, F., Bonaccorso, N., Cilia, S., Contarino, F. M., Di Gaetano, V., Di Gregorio, F., Foresta, A., Furnari, R., Genna, F., Genovese, D., Giorgianni, G., Maida, C. M., Palmeri, S., Parrino, G., Piazza, A., . . . Vitale, F. M. (2025). Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study. Vaccines, 13(12), 1219. https://doi.org/10.3390/vaccines13121219

MLA 9

Costantino, Claudio, et al. “Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study.” Vaccines, vol. 13, no. 12, 2025, p. 1219. https://doi.org/10.3390/vaccines13121219.

Chicago

Costantino, Claudio, Emanuele Amodio, Rosario Asciutto, Costanza Affranchi, Franco Belbruno, Nicole Bonaccorso, Sonia Cilia, et al. 2025. “Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study.” Vaccines 13 (12): 1219. https://doi.org/10.3390/vaccines13121219.

Harvard

Costantino, C. et al. (2025) ‘Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study’, Vaccines, 13(12), p. 1219. doi:10.3390/vaccines13121219.

IEEE

C. Costantino et al., “Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study,” Vaccines, vol. 13, no. 12, p. 1219, 2025, doi: 10.3390/vaccines13121219.

BibTeX

@article{costantino2025impact,
  title     = {{Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study}},
  author    = {Costantino, Claudio and Amodio, Emanuele and Asciutto, Rosario and Affranchi, Costanza and Belbruno, Franco and Bonaccorso, Nicole and Cilia, Sonia and Contarino, Fabio Massimo and Di Gaetano, Vincenzo and Di Gregorio, Francesco and Foresta, Angelo and Furnari, Roberto and Genna, Flavio and Genovese, Dario and Giorgianni, Gabriele and Maida, Carmelo Massimo and Palmeri, Sara and Parrino, Giovanna and Piazza, Alessandra and Addario, Sebastiano Pollina and Tinervia, Giovanni and Tramuto, Fabio and Vitale, Francesco Maria},
  journal   = {Vaccines},
  year      = {2025},
  volume    = {13},
  number    = {12},
  pages     = {1219},
  doi       = {10.3390/vaccines13121219},
  url       = {https://doi.org/10.3390/vaccines13121219}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Epidemiology › Respiratory viral infections research

  • nirsevimab
  • respiratory syncytial virus
  • RSV bronchiolitis
  • universal prophylaxis
  • infants
  • RSV hospitalization
  • Sicily

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Costantino, C., Amodio, E., Asciutto, R., Affranchi, C., Belbruno, F., Bonaccorso, N., Cilia, S., Contarino, F. M., Di Gaetano, V., Di Gregorio, F., Foresta, A., Furnari, R., Genna, F., Genovese, D., Giorgianni, G., Maida, C. M., Palmeri, S., Parrino, G., Piazza, A., . . . Vitale, F. M. (2025). Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study. Vaccines, 13(12), 1219. https://doi.org/10.3390/vaccines13121219

How many times has this paper been cited?

11 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Vaccines: sign in and open the PDF from this page.

Who wrote this paper?

Claudio Costantino, Emanuele Amodio, Rosario Asciutto, Costanza Affranchi, Franco Belbruno, Nicole Bonaccorso, Sonia Cilia, Fabio Massimo Contarino, Vincenzo Di Gaetano, Francesco Di Gregorio, Angelo Foresta, Roberto Furnari and 11 more.

What is the DOI of this paper?

10.3390/vaccines13121219, permanently at https://doi.org/10.3390/vaccines13121219. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.